Anaphylaxis is a condition some people can't avoid, but cost should not be the reason someone cannot access care.
The EpiPen's massive price surge made headlines recently, prompting maker <b>Mylan to make a cheaper generic version</b>.
But the FDA is about to ramp up the device's competition even further. <b> A new blog post from the agency</b> said it was ready to approve new EpiPen competitors as soon as they arrived.
So what's the FDA doing?
The FDA can't regulate drug prices, but has a "road map" to get EpiPen competitors on the market faster, inevitably leading to the cost of EpiPens or equivalent drugs dropping.
The agency has already approved four EpiPen-like auto-injectors, two of which are already on the market. But it insists it can't afford to have "substandard quality products" flood the market and put users' safety at risk.
WATCH | One EpiPen competitor called AdrenaClick has been on the market for years. Here's a clip of how the injector works.
Meanwhile, Mylan CEO Heather Bresch (pictured here) is set to testify before Congress on Sept. 21 regarding its price increases, <b>CNBC reports</b>.
Bresch is the daughter of U.S. Senator Joe Manchin, a Democrat from West Virginia.
WATCH | For more news you need, check out our 60 Second Circa.